Wet AMD: Is combination therapy the way of the future?

Article

Despite recent advances and the promise of new therapies for the treatment of choroidal neovascularization (CNV) resulting from age-related macular degeneration (wet AMD), key challenges remain. These include improving vision outcomes, reducing the numbers of treatments and proving efficacy in different lesion types. While treatment for wet AMD has traditionally centred on monotherapy regimens, the future standard of care may likely focus on combination strategies.

Related Videos
Diana Do, MD, Professor of Ophthalmology, Byers Eye Institute, Stanford University, discusses the PHOTON study results as presented AAO
Dr Ali Erginay discusses his EURETINA presentation
Varun Chaudhary speaks with David Hutton about the 2023 EURETINA congress
Kasperi Kankare at the iCare booth at ESCRS
Colman Cawe, director of fundraising and communications, Orbis UK
© 2023 MJH Life Sciences

All rights reserved.